...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.
【24h】

Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.

机译:在2007年关于罗格列酮的安全警告之后,TRICARE中的​​抗糖尿病药物使用的时间趋势。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To describe utilization patterns for anti-diabetes medications among a cohort of diabetes patients in the Military Health System (MHS) before and after warnings about rosiglitazone issued in May 2007. METHODS: We used segmented regression analysis to compare changes in the level and trend of rosiglitazone utilization and use of other anti-diabetes therapies in the period prior to the drug warnings (between April 2006 and May 2007) and the period after the warnings were issued (between October 2007 and May 2008). RESULTS: The level and trend of rosiglitazone use changed after the highly publicized warnings. The number of prescriptions filled fell by almost 7000 after the warning (p < 0.001). The number of prescriptions filled for pioglitazone, sulfonylureas, and other diabetes drugs increased significantly after the warnings (p < 0.05 in all models). Overall, the level and trend of filled prescriptions per month for all anti-diabetic drugs did not significantly change after the warnings. CONCLUSIONS: Utilization patterns changed in response to warnings about rosiglitazone. While overall utilization of anti-diabetic drugs did not change, further study is needed to determine the associated health outcomes.
机译:目的:描述在2007年5月发布的罗格列酮警告之前和之后,军事卫生系统(MHS)的一组糖尿病患者中抗糖尿病药物的利用模式。方法:我们采用分段回归分析比较了药物水平和水平的变化。罗格列酮在药物警告之前的时期(2006年4月至2007年5月)和警告发布之后的时期(2007年10月至2008年5月)的使用和使用其他抗糖尿病疗法的趋势。结果:在高度宣传的警告后,罗格列酮的使用水平和趋势发生了变化。警告后,开具的处方数量下降了近7000种(p <0.001)。警告后,吡格列酮,磺脲类药物和其他糖尿病药物的处方数量显着增加(在所有模型中,p <0.05)。总体而言,警告后所有抗糖尿病药物的每月处方量和趋势没有明显变化。结论:对罗格列酮的警告提示使利用方式发生了变化。尽管抗糖尿病药物的总体利用没有改变,但仍需要进一步研究以确定相关的健康结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号